Medical/Pharmaceuticals

CStone announces first prescriptions of precision therapy GAVRETO® (pralsetinib) issued across China for the treatment of adults with locally advanced or metastatic RET fusion-positive non-small cell lung cancer after platinum-based chemotherapy

SUZHOU, China, June 21, 2021 /PRNewswire/ -- GAVRETO® (pralsetinib), a precision therapy discovered by CStone Pharmaceuticals' partner Blueprint Medicines, had the first batch of prescriptions issued at Guangdong Province People's Hospital and around 100 other hospitals acrossChina. GAVRETO is al...

2021-06-21 13:06 3911

Study Results of Sintilimab in Combination with Bevacizumab Biosimilar IBI305 for the First-Line Treatment of Hepatocellular Carcinoma Published in The Lancet Oncology

SAN FRANCISCO and SUZHOU, China, June 21, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major dise...

2021-06-21 08:00 8628

EAN Congress: COVID-19 leads to significant cognitive and behavioural problems in patients

VIENNA, June 21, 2021 /PRNewswire/ -- COVID-19 patients suffer from cognitive and behavioural problems two months after being discharged from hospital, a new study presented at the 7th Congress of the European Academy of Neurology has found[1]. Issues with memory, spatial awareness and informati...

2021-06-21 06:01 2795

Bioheng Biotech received Orphan Drug Designation from the U.S. FDA for the treatment of T-ALL.

NANJING, China, June 20, 2021 /PRNewswire/ -- Nanjing Bioheng Biotech Co., Ltd. Announced UCAR T cell therapy product targeting CD7, code CTD401, received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for the treatment of T-cell acute lymphoblastic leukemia (T-ALL...

2021-06-20 21:00 3441

CARsgen Therapeutics officially listing on HKEX

HONG KONG, June 19, 2021 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (the "Company", stock code: 2171.HK) today announced that the Company's Shares have been traded on the Main Board of The Stock Exchange of Hong Kong Limited under the stock code "2171.HK".

2021-06-19 02:57 11413

InnoCare Presents Latest Clinical Data of Orelabrutinib at the16th International Conference on Malignant Lymphoma

BEIJING, June 18, 2021 /PRNewswire/ -- InnoCare (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced today the company presented the latest clinical data of the Bruton's tyrosine kinase (BTK) inhibitor orelabrutinib atthe 16th International Conf...

2021-06-18 17:12 14377

deCODE genetics: Predicting the probability of death

REYKJAVIK, Iceland, June 18, 2021 /PRNewswire/ -- Scientists from deCODE genetics have developed a predictor based on protein measurements in blood samples that predicts the time to all-cause death better than traditional risk factors.

2021-06-18 17:00 4010

China and India Combat Coronavirus Pandemic Together: Online Ceremony Held for the Handover of Medical Supplies to Aid India

HONG KONG, June 18, 2021 /PRNewswire/ -- On 11 June 2021, an online ceremony was held for the handover of anti-pandemic supplies to aidIndia. Medical supplies toIndia included 135 oxygen concentrators, 5 ventilators and 3,300 KN95 masks. Present at the event were Tang Guocai, Chinese Consul Gener...

2021-06-18 16:15 3044

Latest testing confirms Viraleze highly effective against Alpha, Beta and Gamma COVID variants

MELBOURNE, Australia, June 18, 2021 /PRNewswire/ -- New data released today shows thatAustralia's Viraleze™ anti-COVID nasal spray is more than 99.9% effective against three of the four deadliest variants of the SARS-CoV-2 virus. ...

2021-06-18 14:16 15346

Antengene Provides an Update on Its Latest Developments

* Announces two new in-house discovered assets - ATG-031, a potential first-in-class anti-CD24 monoclonal antibody, and ATG-027, a potential first-in-class B7H3/PD-L1 bi-specific antibody * Provides an update on commercial readiness across the Asia Pacific markets for selinexor, Antengene's f...

2021-06-18 14:10 13002

Latest testing confirms Viraleze highly effective against Alpha, Beta and Gamma COVID variants

MELBOURNE, Australia, June 18, 2021 /PRNewswire/ -- New data released today shows thatAustralia's Viraleze™ anti-COVID nasal spray is more than 99.9% effective against three of the four deadliest variants of the SARS-CoV-2 virus. ...

2021-06-18 14:04 14952

Genesis Rapidly Expands its Surgical Device Portfolio to Meet Growing Demand

SINGAPORE, June 18, 2021 /PRNewswire/ -- Genesis MedTech Group (Genesis) is pleased to announce it has completed the acquisition of Horcon, aChina-based suture company, and secured exclusive distributorship rights for Sejong Medical's trocar products inChina. This comes on the back of its recent ...

2021-06-18 11:33 6768

Gilead Sciences Announces Subanalyses of Safety and Efficacy Data from a Phase 2 Study of Chronic Hepatitis B Patients with Renal or Hepatic Impairment Switching to Vemlidy(r)

HONG KONG, June 18, 2021 /PRNewswire/ -- Gilead Sciences, Inc. today announced new sub-analysis data from a Phase 2 open-label study (GS-US-320-4035; NCT03180619), evaluating the safety and efficacy of switching to Vemlidy®#  (tenofovir alafenamide 25 mg, TAF) from tenofovir disoproxil fumarate (T...

2021-06-18 10:00 2563

Nuevocor closes US$24M Series A Financing to Advance Novel Gene Therapies for Cardiomyopathies

SINGAPORE, June 18, 2021 /PRNewswire/ -- Nuevocor, a preclinical-stage biotech company specializing in gene therapy for cardiomyopathies, has announced the completion of an oversubscribed$24 million Series A financing round. The round was co-led by EVX Ventures andBoehringer Ingelheim Venture Fun...

2021-06-18 09:58 10678

Jacobio Announces First Two Patients Dosed in SHP2 Combination Study, Triggering US$20 Million Milestone Payment

BEIJING and SHANGHAI and BOSTON, June 18, 2021 /PRNewswire/ -- Jacobio Pharmaceuticals (1167.HK) has announced that the first two patients have been dosed in the Phase 1/2a clinical trial ofSHP2 inhibitor JAB-3312 in combination with PD-1 antibody Pembrolizumab and MEK inhibitor Binimetinib respe...

2021-06-18 08:31 5357

Innovent Announces First Patient Dosed in the Phase II Basket Trial of Taletrectinib for Solid Tumors with NTRK Fusion

SAN FRANCISCO and SUZHOU, China, June 18, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major disea...

2021-06-18 08:00 4242

RBC Expands Global Youth Charity Program - RBC Charity Day for the Kids

* Virtual celebrations held by RBC Capital Markets employees in Canada, U.S., U.K.,France, Germany, Japan, Hong Kong, Australia, Barbados and Bahamas * US$5 million donated to over 50 charities worldwide SYDNEY, June 18, 2021 /PRNewswire/ -- As part of a global charitable initiative called RBC...

2021-06-17 20:00 2467

Envirotainer Announces Cathay Pacific as First Asian carrier for the recently released Releye® RLP container

STOCKHOLM, June 17, 2021 /PRNewswire/ -- Envirotainer, the global market leader in secure cold chain solutions for air transportation of pharmaceuticals, today announced that Cathay Pacific has approved the Envirotainer Releye® RLP for carriage on its fleet of aircraft. Cathay Pacific can now off...

2021-06-17 19:49 2036

Eccogene announces the addition of Jacques Mizrahi, PhD to Scientific Advisory Board

SHANGHAI, June 17, 2021 /PRNewswire/ -- Eccogene, Inc., a clinical stage biopharmaceutical company focused on discovery and development of metabolic and immunologic therapeutics, announced today the addition ofJacques Mizrahi, Ph.D., to its scientific advisory board.

2021-06-17 19:49 3244

Harbour BioMed Announces Dosing of First Patient of Next-Generation Anti-CTLA-4 Antibody in Combination with PD-1 Antibody in Patients with NSCLC

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, June 17, 2021 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) today announced the dosing of the first patient of HBM4003 in patients with advanced non-small cell lung cancer in its open phase I clinical study. This study will eval...

2021-06-17 15:41 14529
1 ... 636637638639640641642 ... 650